Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
RA-MAP Consortium,John Isaacs,Sarah Brockbank,Ayako Wakatsuki Pedersen,Catharien Hilkens,Amy Anderson,Philip Stocks,Dennis Lendrem,Jessica Tarn,Graham Smith,Ben Allen,John Casement,Julie Diboll,Rachel Harry,Andrew P Cope,Gemma Simpson,Ruth Toward,Hayley Noble,Angela Parke,Wing Wu,Fiona Clarke,David Scott,Ian C Scott,James Galloway,Heidi Lempp,Fowzia Ibrahim,Samana Schwank,Gemma Molyneux,Tomi Lazarov,Frederic Geissmann,Carl S Goodyear,Iain B McInnes,Iona Donnelly,Ashley Gilmour,Aysin Tulunay Virlan,Duncan Porter,Frederique Ponchel,Paul Emery,Jehan El Jawhari,Rekha Parmar,Michael F McDermot,Maya Buch,Benjamin A Fisher,Chris Buckley,Steve P Young,Philip Jones,Karim Raza,Andrew Filer,Costantino Pitzalis,Michael R Barnes,David S Watson,Evan Tzanis,Georgina Thorborn,Liliane Fossati Jimack,Stephen Kelly,Frances Humby,Michele Bombardieri,Sharmila Rana,Zhilong Jia,Katriona Goldmann,Myles Lewis,Michael R Ehrenstein,Gioia Altobelli,Chris John,Sandra Martins,Dao Nguyen,Humayara Ali,Coziana Ciurtin,Jane Worthington,Ian N Bruce,Jamie C Sergeant,Suzanne Mm Verstappen,Fiona Stirling,Adwoa Hughes Morley,Vernon Farewell,Yujie Zhong,Peter C Taylor
DOI: https://doi.org/10.1136/rmdopen-2018-000721
2018-10-25
RMD Open
Abstract:Objectives: To identify predictors of remission and disease activity patterns in patients with rheumatoid arthritis (RA) using individual participant data (IPD) from clinical trials. Methods: Phase II and III clinical trials completed between 2002 and 2012 were identified by systematic literature review and contact with UK market authorisation holders. Anonymised baseline and follow-up IPD from non-biological arms were amalgamated. Multiple imputation was used to handle missing outcome and covariate information. Random effects logistic regression was used to identify predictors of remission, measured by the Disease Activity Score 28 (DAS28) at 6 months. Novel latent class mixed models characterised DAS28 over time. Results: IPD of 3290 participants from 18 trials were included. Of these participants, 92% received methotrexate (MTX). Remission rates were estimated at 8.4%(95%CI 7.4%to9.5%) overall, 17%(95%CI 14.8%to19.4%) for MTX-naïve patients with early RA and 3.2% (95% CI 2.4% to 4.3%) for those with prior MTX exposure at entry. In prior MTX-exposed patients, lower baseline DAS28 and MTX reinitiation were associated with remission. In MTX-naïve patients, being young, white, male, with better functional and mental health, lower baseline DAS28 and receiving concomitant glucocorticoids were associated with remission. Three DAS28 trajectory subpopulations were identified in MTX-naïve and MTX-exposed patients. A number of variables were associated with subpopulation membership and DAS28 levels within subpopulations. Conclusions: Predictors of remission differed between MTX-naïve and prior MTX-exposed patients at entry. Latent class mixed models supported differential non-biological therapy response, with three distinct trajectories observed in both MTX-naïve and MTX-exposed patients. Findings should be useful when designing future RA trials and interpreting results of biomarker studies.